Clinical pharmacokinetics of piroxicam.
Piroxicam is readily absorbed after oral administration. Food and antacids have been shown not to interfere with its bioavailability. Piroxicam is highly bound (approximately 99%) to plasma proteins and has a small distribution volume (approximately 10 l). Despite its high plasma binding, the drug readily penetrates into synovial fluid. Piroxicam has a long elimination half-life of about 50 h. Elimination of the parent drug is mainly the result of biotransformation. The elimination of piroxicam is impaired in some elderly patients, resulting in a high interindividual variability in average steady state levels following a standard 20 mg/day dosage regimen.
D000042:Absorption; D000328:Adult; D000367:Age Factors; D000368:Aged; D001711:Biotransformation; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010894:Piroxicam / Q000008:administration & dosage / Q000378:metabolism*; D012216:Rheumatic Diseases / Q000378:metabolism; D013582:Synovial Fluid / Q000378:metabolism; D014018:Tissue Distribution
D010894:Piroxicam